Kura Oncology
$11.25
49
+$0.12+1.08% Friday 20:00
Statistics
Day High
11.52
Day Low
11.01
52W High
12.14
52W Low
5.54
Volume
2,440,436
Avg. Volume
-
Mkt Cap
978.95M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.89948
Actual EPS
N/A
Financials
-322.89%Profit Margin
Unprofitable107.77MRevenue
-347.97MNet Income
Analyst Ratings
26.5Average Price Target
The highest estimate is 40.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow KURA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap166.82B
Incyte
INCY
Mkt Cap19.41B
Merck
MRK
Mkt Cap302.33B
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Novartis
NVS
Mkt Cap290.05B
AMGEN
AMGN
Mkt Cap183.12B
Pfizer
PFE
Mkt Cap147.62B
Roche
RHHBY
Mkt Cap343.56B
About
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Employees
192
Country
United States
ISIN
US50127T1097
Listings
0 Comments
Share your thoughts
FAQ
What is Kura Oncology stock price today?▼
The current price of KURA is $11.25 USD — it has increased by +1.08% in the past 24 hours. Watch Kura Oncology stock price performance more closely on the chart.
What is Kura Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kura Oncology stocks are traded under the ticker KURA.
Is Kura Oncology stock price growing?▼
KURA stock has risen by +25.56% compared to the previous week, the month change is a +21.49% rise, over the last year Kura Oncology has showed a +99.47% increase.
What is Kura Oncology market cap?▼
Today Kura Oncology has the market capitalization of 978.95M
When is the next Kura Oncology earnings date?▼
Kura Oncology is going to release the next earnings report on July 30, 2026.
What were Kura Oncology earnings last quarter?▼
KURA earnings for the last quarter are -0.83 USD per share, whereas the estimation was -0.83 USD resulting in a +0.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kura Oncology revenue for the last year?▼
Kura Oncology revenue for the last year amounts to 107.77M USD.
What is Kura Oncology net income for the last year?▼
KURA net income for the last year is -347.97M USD.
How many employees does Kura Oncology have?▼
As of May 26, 2026, the company has 192 employees.
In which sector is Kura Oncology located?▼
Kura Oncology operates in the Health & Wellness sector.
When did Kura Oncology complete a stock split?▼
Kura Oncology has not had any recent stock splits.
Where is Kura Oncology headquartered?▼
Kura Oncology is headquartered in San Diego, United States.